Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Data solutionsForge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Index solutionsForge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Forge Thematic BasketsExplore focused views into key private market themesLiquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary marketplace / Explore private companies / Parabilis Medicines IPO
Parabilis Medicines

Parabilis Medicines IPO

$681.2MM
Series F Valuation, Jan 2026
Register for details
For more details on financing and valuation of private companies similar to Parabilis Medicines before its IPO, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Parabilis Medicines IPO date and status

2016
Founded
May 2026
S-1 Filed
Jun 2026
IPO Completed

Company details

FogPharma, based in Cambridge, Mass., was founded in 2016 by several scientists including Gregory Verdine, the company’s chairman and CEO, Weiging Zhou, David Lane, and Gerard Hilinski. The company, which was valued at $406 million in November 2022, is developing a new class of drugs designed to treat cancerous tumors that have remained elusive to other approaches.

In November 2022, FogPharma closed a $178 million Series D round led by a group of investors including Arch Venture Partners and Invus.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Founded
2016
Headquarters
Cambridge, MA, United States
Founders
John McGee, Ph.D.
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Post-Money Valuation 3
$681.2MM
Total Funding
$811.88MM
Last Funding Round
Series F

Learn more about Parabilis Medicines

To invest in Parabilis Medicines pre-IPO

Can you invest in Parabilis Medicines pre-IPO?

You may invest in Parabilis Medicines as it is a public company listed on the NASDAQ with ticker PBLS. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Parabilis Medicines before it goes public?

You can no longer sell shares of Parabilis Medicines on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Parabilis Medicines shares?

Forge can no longer determine the value of Parabilis Medicines shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Parabilis Medicines a publicly traded company?

Parabilis Medicines became a public company following its IPO on 06/10/2026 and is now traded on the NASDAQ under the ticker PBLS.

To learn more about Parabilis Medicines potential IPO

Will Parabilis Medicines go IPO?

Parabilis Medicines became a public company following its IPO on 06/10/2026 and is now traded on the NASDAQ under the ticker PBLS.

What is Parabilis Medicines’ IPO price?

The IPO price of Parabilis Medicines is not currently available.

When was Parabilis Medicines founded?

Parabilis Medicines was founded in 2016.

What is Parabilis Medicines funding to date?

Parabilis Medicines has raised $811.88MM to date.

Parabilis Medicines major investors

6 Dimensions Capital
Arch Venture Partners
Blue Pool Capital
Boyu Capital
Casdin Capital
Catalio Capital Management
Cormorant Asset Management
Deerfield Management
Farallon Capital Management
Fidelity Management & Research
Foresite Capital
General Catalyst
Gv
Hbm Healthcare Investments
Horizons Ventures
Leerink Partners
Milky Way Investments Group
Pagsgroup
Pivotal Life Sciences
Ra Capital Management
Rock Springs Capital
Samsara Biocapital
Sixty Degree Capital
Symbiosis Capital Management
T. Rowe Price
The Invus Group
Venbio
Wuxi Apptec

Parabilis Medicines pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
01/08/2026 Series F $305.25MM $6.16 $681.2MM Alderline Group, Arch Venture Partners, Catalio Capital Management, Cormorant Asset Management, Farallon Capital Management, Fidelity, Foresite Capital, Frazier Life Sciences, General Catalyst, Gv, Hbm Healthcare Investments, Invus, Janus Henderson Investors, Marshall Wace, Milky Way Investments, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Soleus Capital, T. Rowe Price, Venbio Partners
Price per Share
$ xx.xx
Shares Outstanding
49,518,175
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alderline Group, Arch Venture Partners, Catalio Capital Management, Cormorant Asset Management, Farallon Capital Management, Fidelity, Foresite Capital, Frazier Life Sciences, General Catalyst, Gv, Hbm Healthcare Investments, Invus, Janus Henderson Investors, Marshall Wace, Milky Way Investments, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Soleus Capital, T. Rowe Price, Venbio Partners
01/22/2025 Series E $145MM $6.23 $491.8MM Alex Gorsky, Catalio Capital Management, Foresite Capital, General Catalyst, Marshall Wace, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Symbiosis
Price per Share
$ xx.xx
Shares Outstanding
23,281,563
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
0.7x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alex Gorsky, Catalio Capital Management, Foresite Capital, General Catalyst, Marshall Wace, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Symbiosis
11/21/2022 Series D $178MM $10.76 $406.53MM Arch Venture Partners, Casdin Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Fidelity, Gv, Hbm Healthcare Investments, Invus, Milky Way Investments, Pagsgroup, T. Rowe Price, Venbio Partners
Price per Share
$ xx.xx
Shares Outstanding
16,537,979
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
0.8x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Arch Venture Partners, Casdin Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Fidelity, Gv, Hbm Healthcare Investments, Invus, Milky Way Investments, Pagsgroup, T. Rowe Price, Venbio Partners
03/01/2021 Series C $107MM $14.49 $262.08MM 6 Dimensions Capital, Blue Pool Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Gv, Invus, Venbio Partners
Price per Share
$ xx.xx
Shares Outstanding
7,384,710
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
0.9x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
6 Dimensions Capital, Blue Pool Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Gv, Invus, Venbio Partners
05/16/2018 Series B $65.51MM $14.06 $131.82MM 6 Dimensions Capital, Blue Pool Capital, Boyu Capital, Deerfield Management, Gv, Horizons Ventures, Lerrink Partners, Nan Fung Group, Wuxi Apptec Corporate Ventures
Price per Share
$ xx.xx
Shares Outstanding
4,658,112
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
0.9x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
6 Dimensions Capital, Blue Pool Capital, Boyu Capital, Deerfield Management, Gv, Horizons Ventures, Lerrink Partners, Nan Fung Group, Wuxi Apptec Corporate Ventures
05/25/2016 Series A $11.11MM $7.75 $37.05MM Deerfield Management
Price per Share
$ xx.xx
Shares Outstanding
1,434,062
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
0.7x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Deerfield Management

Parabilis Medicines IPO news and media highlights

Parabilis, chasing ‘undruggable’ targets, nabs $305M amid VC funding blitz

Parabilis Medicines, formerly known as FogPharma, raised $305 million in a Series F financing to support its mission of pursuing disease targets long dismissed as out of reach by modern science.

FogPharma pulls in $145M to support cancer drug research

FogPharma elevated its financing with a series E funding round to continue its cancer pharmaceutical research expansion.

FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs.

FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.

FogPharma Nets $178M Series D to Tackle Tough Targets

FogPharma has netted a $178 Million Series D financing to develop Helicon polypeptide therapeutics against hard targets.
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
OURAOURANot available$ xx.xxNot available------
FreenomeFreenomeNot available$ xx.xxSeries F$2.05B$7.40$263.96MM
KardiganKardiganNot available$ xx.xxSeries B-1$1.6B$21.37$80.78MM
OriginOriginNot available$ xx.xxNot available------
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Top Gainers

Company Forge Price (6M Change) Market Activity Last Matched
Vulcan Elements Vulcan Elements $90.25 +$78.75 (684.78%)Medium $xxx.xx
Crusoe Crusoe $225.00 +$140.99 (167.83%)Limited $xxx.xx
SandboxAQ SandboxAQ $41.35 +$25.86 (166.95%)High $xxx.xx
SambaNova Systems SambaNova Systems $35.00 +$21.00 (150.00%)Medium $xxx.xx
Whoop Whoop $6.51 +$3.86 (145.66%)Medium $xxx.xx

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic Not availableHigh $xxx.xx
OpenAI OpenAI $721.85 +$0.15 (0.02%)High $xxx.xx
Anduril Anduril $116.68 -$0.30 (0.26%)High $xxx.xx
Databricks Databricks $242.04 +$17.04 (7.57%)High $xxx.xx
Figure AI Figure AI $174.00 -$20.00 (10.31%)Limited $xxx.xx

Forge, your trusted partner for pre-IPO insights and FogPharma data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Jun 12, 2026

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.